Brain metastasis - Evidence based management

Journal of Cancer Research and Therapeutics

Volumn 2, Issue 1, 2006, Pages 5-13

  Biswas, G ^a   Bhagwat, R ^a   Khurana, R ^a   Menon, H ^a   Prasad, N ^a   Parikh, P M ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Brain Metastasis; Management; Temozolomide

Indexed keywords

EID: 32844461627     PISSN: 09731482     EISSN: 09731482     Source Type: Journal    
DOI: 10.4103/0973-1482.19768     Document Type: Review

References (88)

1. Posner JB. Neurologic Complications of Cancer. F.A. Davis Company: Philadelphia; 1995.
2. Davey P. Brain metastases: Treatment options to improve outcomes. CNS Drugs 2002;16:325-38.
3. Ewend MG, Carey LA, Morris DE, Harvey RD, Hensing TA. Brain metastases. Curr Treat Options Oncol 2001;2:537-47.
4. Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin N Am 2003 21:1-23.
5. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol 1998;45:741-4.
6. Subramanian A, Harris A, Piggott K, Shieff C, Bradford R. Metastasis to and from the central nervous system - the 'relatively protected site'. Lancet Oncol 2002;3:498-507.
7. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983;52:2349-54.
8. th edn. 2004. p. 1227-31.
9. Wen PY, Shafman TD. Site-specific therapy of metastatic breast cancer. In: Harris JR, editor. Disease of the Breast. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 841-53.
10. DeAngelis LM, Loeffler JS, Mamelak AN. Metastatic brain tumors. Cancer management: a multidisciplinary approach. 607-14.
11. Mehta MP, Tremont I. Brain metastases. In: Furie B, Cassileth P, Atkins MB, Mayer RJ editors): Clinical Hematology and Oncology: Presentation, Diagnosis and Treatment. Philadelphia, PA: Churchill Livingstone; 2003. p. 1062-76.
12. Levin VA, Prados MR, Wara WM, Davis RL, Gutin PH, Phillips TL, et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995;32:75-83.
13. DeAngelis LM, Gutin PH, Leibel SA, et al, editors. Intracranial tumors: diagnoses and treatment. London: Martin Dunitz; 2002. p. 367-94.
14. Chao JH, Phillips R, Nickson JJ. Roentgenray therapy for cerebral metastases. Cancer 1954;7:682-9.
15. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, et al. The palliation of brain metastases: final results of two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 1980;6:1-9.
16. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 1981;7:891-5.
17. Sause WT, Scott C, Krisch R, Rotman M, Sneed PK, Janjan N, et al. Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28. Int J Radiat Oncol Biol Phys 1993;26:653-7.
18. Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 1997;39:571-4.
19. Taimur S, Edelman MJ. Treatment options for brain metastases in patients with non-small cell lung cancer. Curr Treat Options Oncol 2003;4:89-95.
20. Regine WF, Scott C, Murray K, Curran W. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: An analysis from Radiation Therapy Oncology Group study 91-04. Int J Radiat Oncol Biol Phys 2001;51:711-7.
21. Chang SD, Adler JR. Current treatment of patients with multiple brain metastases. Neurosurg Focus 2000;9.
22. DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fuks Z, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 1989;24:798-805.
23. DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fuks Z, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 1989;24:798-805.
24. Asai A, Matsutani M, Kohno T, Nakamura O, Tanaka H, Fujimaki T, et al. Subacute brain atrophy after radiation therapy for malignant brain tumor. Cancer 1989;63:1962-74.
25. Amorino GP, Lee H, Holburn GE, Paschal CB, Hercules SK, Shyr Y, et al. Enhancement of tumor oxygenation and radiation response by the allosteric effectors of hemoglobin, RSR13. Radiat Res 2001;156:294-300.
26. Suh JH. A phase 3, randomized, open-label, comparative study of standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13, in patients with brain metastases. Neurooncol 2003;5:345-6.
27. Magda D, Lepp C, Gerasimchuk N, Lee I, Sessler JL, Lin A, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001;51:1025-36.
28. Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001;19:2074-83.
29. Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive and neurologic end points. J Clin Oncol 2002;20:3445-53.
30. Xu S, Zakian K, Thaler H, Matei C, Alfieri A, Chen Y, et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 2001;49:1381-90.
31. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;1:2529-36.
32. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
33. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Huntingt) 1999;12:941-54,957-61;discussion 961-62,969.
34. Lang FF, Sawaya R. Surgical management of cerebral metastases. Neurosurg Clin N Am 1996;7:459-84.
35. Sperduto PW. A review of stereotactic radiosurgery in the management of brain metastases. Technol Cancer Res Treat 2003;2:105-10.
36. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
37. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29:711-7.
38. Wronski M, Arbit E, McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer 1997;80:1746-54
39. Pieper DR, Hess KR, Sawaya RE. Role of surgery in the treatment of brain metastases in patients with breast cancer. Ann Surg Oncol 1997;4:481-90.
40. Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg 1993;79.210-6.
41. Loeffler J, Alexander E. Radiosurgery for the treatment of intracranial metastases. In: Loeffler JS, editor. Stereotactic Radiosurgery. New York: McGraw-Hill; 1993. p. 197-206.
42. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;3:583-90.
43. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78:1470-6.
44. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys1999;45:427-34.
45. Chougule PB, Burton-Williams M, Saris S. Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both. Int J Radiat Oncol Biol Phys 2000;8:114.
46. Andrews DW, Scott C, Sperduto PW. Phase III randomized trial comparing whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Results of the RTOG 9508 trial. Lancet 2004;63:1665-73.
47. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989;7:916-22.
48. Cocconi G, Lottici R, Bisagni G, Bacchi M, Tonato M, Passalacqua R, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990;8:327-34.
49. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58:832-9.
50. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69:972-80.
51. Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid harmacokinetics of temozolomide. Proc Am Soc Clin Oncol 1995;14:461a.
52. Newlands ES, Stevens MF, Wedge SR et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
53. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-51.
54. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomised phase III study of temozolamide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2003;18:158-66.
55. Dziadziuszko R, Ardizzoni A, Postmus PE, Smit EF, Price A, Debruyne C, et al. Temozolamide in patients with advanced non-small-cell lung cancer with and without brain metastasis: a phase II study of the EORTC Lung Cancer Group. Eur J Cancer 2003;39:1271-6.
56. Adonizion CS, Babb JS, Maiala C, Huang C, Donahue J, Millenson MM, et al. Temozolamide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients. Clin Lung Canc 2002;3:254-8.
57. Friedman HS, Evans B, Reardon D. Phase II trial of temozolamide for patients with progressive brain metastasis. Proc Am Soc Clin Oncol 2003;22:408.
58. Siena S, Lanonio G, Baietta E. Multicenter phase II study of temozolamide therapy for brain metastasis in patients with malignant melanoma, breast cancer and non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:102.
59. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;2:249-54.
60. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53:259-65.
61. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, et al. Phase II randomized trial of temozolamide and concurrent radiotherapy in patients with brain metastasis. J Clin Oncol 2002;20:3644-50.
62. Verger E, Gil M, Yaya R. Concomitant temozolamide and whole brain radiotherapy in patients with brain metastasis: randomized multicentric phase II study. Proc Am Soc Clin Oncol 2003;22:101.
63. Dardoufas C, Miliadou A, Skarleas C. Concomitant temozolomide (TMZ) and radiotherapy (RT) followed by adjuvant treatment with temozolomide in patients with brain metastases from solid tumors. Proc Am Soc Clin Oncol 2001;0:75b.
64. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of Brain Metastases associated with metastatic melanoma: A Phase II Study. J Clin Oncol 2004;22:2101-7.
65. Giorgio CG, Giuffrida D, Pappalardo A, Russo A, Santini D, Salice P, et al. Oral Temozolomide in heavily pre-treated brain metastasis from non-small cell lung cancer: Phase II study. Lung Cancer 2005 (article in press).
66. Christodoulou C, Bafaloukos D, Linardor H, Aravantinos G, Bamias A, Carina M, et al. Temozolomide combined with cisplatin in patients with brain metastasis from solid tumors: a Helenic Cooperative Oncology Group (HeCOG) Phase II Study. J Neuro Oncol 2005;71:61-5.
67. Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-52.
68. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001;83:257-62.
69. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993;53:725-7.
70. Oberhoff C, Kieback DG, Wurstlein R, Deertz H, Sehouli J, van Soest C, et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001;24:256-60.
71. Manegold C, Pawel JV, Scheithauer W. Response of SCLC brain metastases on topotecan (SK and F 104864) therapy. Ann Oncol 1996;7:106-7.
72. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-6.
73. Depierre A, von Pawel J, Hans K. Evaluation of topotecan (Hycamtin TM) in relapsed small cell lung cancer (SCLC): a multicentre phase II study. Lung Cancer 1997;18:35.
74. Scutte W, Manegold C, von Pawel JV, Lan J, Schafer B, Kaubitzsch S, Staab HJ, et al. Topotecan - a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol 1999;33:354-63.
75. Korfel A, Oehm C, von Pawel J, Keppler U, Deppermann M, Kaubitsch S, et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation: a multicentre phase II study. Eur J Cancer 2002;38:1724-9.
76. Schutte W, Manegold C, von Pawel JV, Lan J, Schafer B, Kaubitzsch S, et al. Topotecan in the therapy of brain metastases in lung cancer. Onkologie 1998;21:25-7.
77. Fisher BJ, Scott C, Macdonald DR, Coughlin C, Curran WJ. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol 2001;19:1111-7.
78. Fisher B, Won M, Macdonald D, Johnson DW, Roa W. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 2002;53:980-6.
79. Eckardt JR, Martin KA, Schmidt AM. A phase I trial of IV topotecan in combination with oral temozolamide daily times 5 every 28 days. Proc Am Soc Clin Oncol 2002;21:83b.
80. Glantz M, Choy H, Chakravarthy A. A randomized phase III trial of concurrent paclitaxel and whole brain radiotherapy (WBRT) vs. WBRT alone for brain metastases. Proc Am Soc Clin Oncol 1999;18:140a.
81. Glantz M, Choy H, Chakravarthy A. Proc Am Soc Clin Oncol (abstr 535) 2001;49:1381-90.
82. Kim JH, Kim SH, Kolozsvary A, Khil MS. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase 1. Int J Radiat Oncol Biol Phys 1992;22:515-8.
83. Reboul F, Vincent P, Brewer Y. Chemoradiation for brain metastasis of lung origin. Results of a phase II study. Proc Am Soc Clin Oncol 1996;15:373.
84. Robinet G, Thomas P, Breton JL. Phase III study of early versus delayed whole brain radiotherapy (WBRT) with concurrent cisplatin and vinorelbine combination in brain metastasis (BM) of non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;17:453a.
85. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M, et al. Dramatic effect of ZD1839 ("Iressa") in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 2003;40:73-6.
86. Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 2003;4:656-8.
87. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial. Ann Oncol 2004;5:1042-7.
88. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803.